Industries > Pharma > Global Stem Cell Technologies and Applications Market 2018-2028

Global Stem Cell Technologies and Applications Market 2018-2028

Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

PUBLISHED: 02 March 2018
PAGES: 284
PRODUCT CODE: PHA0291

Clear
WOOCS 2.2.1

The global stem cell technologies and applications market is estimated to have reached $12,040 million and is expected to grow at a CAGR of 13.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 11.5% from 2017 to 2028.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 284-page report you will receive 114 charts– all unavailable elsewhere.

The 284-page report provides clear detailed insight into the global stem cell technologies and applications market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Stem Cell Technologies and Applications Market 2018-2018

Report Scope

Global Stem Cell Technologies and Applications Market forecasts from 2018-2028

Global Stem Cell Technologies and Applications submarket forecasts from 2018-2028:
• Cancer treatment
• Cardiovascular therapy
• CNS
• Other therapies
• Non-therapeutic applications

Individual revenue forecast to 2028 for selected top products:
• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST)

• Analysis of the most promising pipeline therapies in each therapeutic segment

• Discussion on regulatory environments and developments in the US, Japan, Europe and other leading countries

• Analysis of what drives and restrains the market

• This study also discusses other influences on that field, including these:
• Haematopoietic stem cell transplantation (HSCT)
• Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
• Uses for umbilical cord blood and related technologies, including cellular and blood banking
• Agents for osteogenesis and treating autoimmune conditions
• Applications in cell-based assays, diagnostics and drug development.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market. You find data, trends and predictions.

Buy our report today Global Stem Cell Technologies and Applications Market 2018-2018: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Stem Cell Technologies and Applications Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Stem Cell Technologies and Applications Market 2018-2028


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories